Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10234 and Emtricitabine Interaction Study
NCT04477096Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of polyethylene glycol loxenatide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Pharmacokinetics parameters of HS-10234, its metabolite tenofovir, and Emtricitabine. Started Aug 2020; status: completed.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04477096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04477096.